Hormone IUD to preserve fertility in early uterine cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years old or younger
- You strongly want to keep the possibility of future pregnancy (fertility preservation)
- Your biopsy shows a specific diagnosis: grade 1 endometrial cancer with progesterone receptor positivity, or atypical endometrial hyperplasia
- Imaging shows disease is limited to the uterus lining (for cancer; stage 1A by MRI)
- Your blood test CA125/199 is normal (for cancer), and a procedure may be needed to rule out spread to ovaries/other sites
- You can take the study treatments safely and agree to regular follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a weight-management approach plus a progesterone-releasing IUD (LNG-IUS) and megestrol to treat endometrial atypical hyperplasia, a high-risk precancer of the uterine lining. It may help shrink or control the abnormal cells while supporting fertility or keeping the uterus.
This study tests whether the medicine tirzepatide, which is used for weight loss, can help women with early-stage endometrial cancer or a pre-cancerous condition avoid or delay surgery. It combines taking tizepatide with a hormonal intrauterine device (Mirena) to try to shrink or stop the cancer from growing.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This trial tests a new treatment for very early endometrial cancer or a precancerous condition, aiming to help you avoid a hysterectomy and keep the chance of having children. It combines a medication (mazdutide) that helps with weight and hormone problems with a hormonal intrauterine device (LNG-IUS) to treat the lining of the womb.
This trial tests whether adding GnRH medicine and letrozole to standard progestin treatment can better control early, low-risk endometrial cancer or atypical hyperplasia in people who are not obese. It may help some patients avoid progression while keeping the uterus, especially for those wanting future fertility.
This study looks at how ultrasound and tissue samples (histology) can better guide fertility-sparing treatment for early uterine cancer or precancer. It aims to improve how doctors decide on surgery or hormone therapy to preserve fertility.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.